Non-Hodgkin Lymphoma | Specialty

Treating Relapsed Diffuse Large B-Cell Lymphoma

June 30th 2015

Diffuse Large B-Cell Lymphoma Treatment Regimens

June 30th 2015

Management of Refractory Follicular Lymphoma

June 30th 2015

Stem Cell Transplantation in Follicular Lymphoma

June 30th 2015

Frontline Treatments for Follicular Lymphoma

June 30th 2015

Ibrutinib in Waldenström's Macroglobulinemia

June 30th 2015

B-Cell Receptor Inhibitor Response Criteria in CLL

June 30th 2015

Emerging Strategies in CLL and Follicular Lymphoma

June 30th 2015

Ibrutinib-Associated Adverse Events

June 30th 2015

Ibrutinib Monotherapy and Combinations in CLL

June 30th 2015

Preventing Infusion Reactions With CD20 Antibodies in CLL

June 30th 2015

Role of B-Cell Receptor Signaling Inhibitors in CLL

June 30th 2015

Changing Treatment Landscape in CLL

June 30th 2015

Adding Brentuximab Vedotin to R-CHOP Induces 80% Response Rate in DLBCL

June 26th 2015

Combining the CD30-directed antibody-drug conjugate brentuximab vedotin with R-CHOP yielded objective responses in 80% of patients with advanced DLBCL in a phase II trial.

Novel Combination Strategies Explored in Two Phase III NHL Studies

June 26th 2015

John P. Leonard, MD, discusses the phase III SELENE and AUGMENT trials, along with smaller investigations, which hope to uncover more efficacious treatments for patients with NHL.

Cheson on Obinutuzumab's Potential for Patients With Rituximab-Refractory iNHL

June 24th 2015

OncLive spoke with Bruce D. Cheson, MD, to gain a deeper understanding about the significance of the GADOLIN study results.

Dr. Leonard on Lenalidomide With Rituximab in Follicular Lymphoma

June 24th 2015

John P. Leonard, MD, medical oncology, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, discusses an ongoing study examining the use of lenalidomide combined with rituximab in patients with recurrent follicular lymphoma.

Martin Barrett on Intravenous Versus Subcutaneous Rituximab

June 20th 2015

Martin Barrett, PhD, Clinical Scientist at Hoffmann-La Roche, discusses a study which compared intravenous (IV) rituximab to subcutaneous rituximab in non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL).

CAR-Modified T-Cell Therapy Shows Durable Response in Non-Hodgkin Lymphoma

June 20th 2015

Infusions of CTL019 achieved durable responses and showed an acceptable safety profile in heavily pretreated patients with CD19-positive non-Hodgkin lymphoma.

Dr. Atanasio on Ibrutinib and Obinuzutumab Combination in CLL/SLL

June 20th 2015

Carolina Moreno Atanasio, MD, University of Barcelona, discusses an ongoing phase III study comparing ibrutinib and obinutuzumab with chlorambucil and obinutuzumab in treatment-naïve patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).